MarketCap
Facebook
X
Telegram
INVO Bioscience Income Statement 2025-2010 | INVO
Brief overview of financial results at INVO Bioscience
The conclusions below are based on five years of reported results. Revenue at INVO Bioscience moved from 1 million dollars in 2020 to 6.8 million dollars in 2025. Overall revenue changed by +559.5%, equal to an annualized rate of about 45.8%. This pace points to rapid expansion of the business.
The five-year change in gross profit reached +618%: from $949 thousand to $6.8 million. Cost of revenue developed more favorably than sales, supporting gross profitability. Gross margin moved from 91.4% to 99.6%. The margin shift points to a more favorable sales-and-cost structure.
The operating result measured by EBITDA moved from −5.5 million dollars to −6.6 million dollars, or −19.7%. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −528.3% to −95.9%. The company improved its ability to convert sales into EBITDA.
Net income moved from −$8.3 million at the start to −$23.3 million at the end. The period ended with a larger loss than it began with.
What the figures show
The figures do not all move in the same direction. Key strengths include an improving EBITDA margin, a larger revenue base and improving gross profitability. The weaker side of the profile includes a weaker final result and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement INVO Bioscience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | 90.6 K | 285 K | 33.8 M | 14.5 M | 39.1 M | 69.4 M | 16.3 M | 49.2 M | 68.5 M | 22.4 M | 2.91 M | 997 K | 3.16 M | - |
Shares |
117 K | 2.51 K | 119 K | 606 K | 10.6 M | 4.88 M | 4.88 M | 4.82 M | 4.44 M | 4.39 M | 4.28 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | - |
Historical Prices |
- | - | 0.76 | 0.47 | 3.18 | 2.96 | - | - | - | - | - | - | - | - | - | - |
Net Income |
-23.3 M | -9.26 M | -8.03 M | -10.9 M | -6.65 M | -8.35 M | -2.17 M | -3.08 M | -702 K | -2.12 M | -4.96 M | -1.73 M | -761 K | -666 K | -797 K | - |
Revenue |
6.84 M | 6.53 M | 3.02 M | 822 K | 4.16 M | 1.04 M | 1.48 M | 494 K | 282 K | 50.9 K | 11.7 K | 16.6 K | 27.1 K | 56.4 K | 71.5 K | - |
Cost of Revenue |
30.6 K | 12.2 K | 1.97 M | 332 K | 145 K | 88.8 K | 140 K | 90.4 K | 52 K | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 491 K | 4.02 M | 949 K | 1.34 M | 404 K | 230 K | 35.8 K | 3.88 K | 8.91 K | 16.5 K | 35.5 K | 53.6 K | - |
Operating Income |
-7.24 M | -6.63 M | -6.77 M | -10.6 M | -5.22 M | -5.51 M | -1.79 M | -2.63 M | -640 K | -2.11 M | -595 K | -1.68 M | -605 K | -552 K | -703 K | - |
Interest Expense |
- | - | 926 K | 59.4 K | 1.27 M | 2.84 M | 388 K | 442 K | 20.9 K | 13.8 K | 32 K | 51.9 K | 51.9 K | 92.9 K | 156 K | - |
EBITDA |
-6.56 M | -5.71 M | -6.57 M | -10.5 M | -5.19 M | -5.48 M | -1.76 M | -2.63 M | -638 K | -2.11 M | -589 K | -1.67 M | -594 K | -541 K | -682 K | - |
Operating Expenses |
- | - | 9.79 M | 11.4 M | 9.23 M | 6.46 M | 3.13 M | 3.04 M | 871 K | 2.15 M | 599 K | 1.69 M | 622 K | 588 K | 757 K | - |
General and Administrative Expenses |
7.69 M | 8.07 M | 704 K | 9.98 M | 9.02 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement INVO Bioscience
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.64 M | 3.45 M | 397 K | 1.39 M | 124 K | 108 K | 100 K | 211 K | 2.49 M | 1.78 M | 732 K | 623 K | 609 K | 608 K | 606 K | 12.1 M | 11.9 M | 10.5 M | 10.4 M | 9.89 M | 9.64 M | 4.95 M | 4.93 M | 4.92 M | 4.88 M | 4.86 M | 7.76 M | 154 M | 154 M | 147 M | 147 M | 143 M | 142 M | 141 M | 141 M | 141 M | 141 M | 141 M | 138 M | 137 M | 137 M | 133 M | 126 M | 120 M | 120 M | 111 M | 111 M | 111 M | 111 M | 110 M | 107 M | 104 M | 93.5 M | 91.2 M | 87.9 M | 85.4 M | 83.1 M | 78.6 M | 77.7 M | - |
Net Income |
-5.54 M | -2.64 M | -5.28 M | -17.4 M | - | -1.63 M | -2.25 M | -1.6 M | - | -1.25 M | -2.24 M | -2.55 M | - | -2.55 M | -2.8 M | -2.77 M | - | -2.24 M | -1.82 M | -2.45 M | - | -1.77 M | -1.32 M | -1.44 M | - | -710 K | -242 K | 459 K | - | -295 K | -1.87 M | -145 K | - | -149 K | -137 K | -215 K | - | -211 K | -1.46 M | -181 K | - | -123 K | -4.45 M | -145 K | - | -118 K | -187 K | -117 K | - | -214 K | -105 K | -303 K | - | -240 K | -139 K | -244 K | - | -99.2 K | -307 K | - |
Revenue |
2.02 M | 1.76 M | 1.86 M | 1.64 M | - | 1.43 M | 1.84 M | 1.58 M | - | 975 K | 316 K | 348 K | - | 235 K | 146 K | 163 K | - | 219 K | 208 K | 685 K | - | 336 K | 246 K | 259 K | - | 304 K | 659 K | 189 K | - | 125 K | 110 K | 104 K | - | 68.2 K | 80.3 K | 52.2 K | - | 17.8 K | 5.45 K | 18.1 K | - | 2.51 K | 5.55 K | 3.62 K | - | 4.75 K | 2.16 K | 9.67 K | - | 297 | 3.62 K | 8.28 K | - | 3.62 K | 12.7 K | 11.3 K | - | 12.9 K | 21.8 K | - |
Cost of Revenue |
5.15 K | - | - | 1.06 M | - | 988 K | 862 K | 862 K | - | 581 K | 236 K | 231 K | - | 109 K | 78.3 K | 65 K | - | 20.4 K | 14.6 K | 62.7 K | - | 27.4 K | 21.2 K | 30 K | - | 44.9 K | 55.3 K | 11 K | - | 15.4 K | 16.7 K | 14.4 K | - | 12.8 K | 14.2 K | 13.8 K | - | 6.45 K | 2.38 K | 3.16 K | - | 4.41 K | -466 | 2.21 K | - | 1.9 K | 1.75 K | 2.63 K | - | 1.07 K | 1.67 K | 2.44 K | - | 1.99 K | 5.01 K | 866 | - | 3.26 K | 6.37 K | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | 275 K | - | 126 K | 67.9 K | 97.6 K | - | 198 K | 194 K | 622 K | - | 309 K | 225 K | 229 K | - | 259 K | 603 K | 178 K | - | 110 K | 93.5 K | 89.7 K | - | 55.4 K | 66.1 K | 38.4 K | - | 11.4 K | 3.06 K | 14.9 K | - | -1.9 K | 6.02 K | 1.42 K | - | 2.85 K | 413 | 7.05 K | - | -777 | 1.95 K | 5.83 K | - | 1.63 K | 7.66 K | 10.4 K | - | 9.62 K | 15.4 K | - |
Operating Income |
-1.59 M | -1.64 M | -2.99 M | -17.1 M | - | -1.3 M | -1.85 M | -1.51 M | - | -886 K | -2.07 M | -2.31 M | - | -2.53 M | -2.68 M | -2.7 M | - | -2.27 M | -1.89 M | -1.56 M | - | -1.27 M | -1.06 M | -1.4 M | - | -632 K | -65.8 K | -349 K | - | -190 K | -1.79 M | -140 K | - | -144 K | -132 K | -167 K | - | -207 K | -1.45 M | -181 K | - | -119 K | -107 K | -132 K | - | -105 K | -174 K | -104 K | - | -124 K | -150 K | -191 K | - | -160 K | -160 K | -116 K | - | -172 K | -205 K | - |
Interest Expense |
- | - | - | -311 K | - | - | - | -181 K | - | 352 K | 175 K | 217 K | - | 1.76 K | 102 | 1.46 K | - | 92.5 K | 91.1 K | 895 K | - | 504 K | 260 K | 47.9 K | - | 47.5 K | 176 K | 109 K | - | 105 K | 74.7 K | 4.44 K | - | 4.55 K | 4.56 K | 7.3 K | - | 3.45 K | 3.63 K | 648 | - | 4.43 K | 7.67 K | 12.8 K | - | 13.1 K | 12.9 K | 12.8 K | - | 13.1 K | 12.9 K | 12.8 K | - | 13.1 K | 12.9 K | 13.2 K | - | - | - | - |
EBITDA |
-1.45 M | -1.5 M | -2.82 M | -16.9 M | - | -1.07 M | -1.62 M | -1.28 M | - | -866 K | -2.05 M | -2.29 M | - | -2.51 M | -2.66 M | -2.69 M | - | -2.25 M | -1.88 M | -1.56 M | - | -1.26 M | -1.06 M | -1.39 M | - | -625 K | -62.3 K | -347 K | - | -186 K | -1.79 M | -139 K | - | -143 K | -132 K | -167 K | - | -205 K | -1.45 M | -179 K | - | -115 K | -105 K | -130 K | - | -105 K | -174 K | -102 K | - | -124 K | -150 K | -189 K | - | -160 K | -160 K | -114 K | - | -172 K | -205 K | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | 1.86 M | 2.38 M | 2.58 M | - | 2.76 M | 2.83 M | 2.8 M | - | 2.47 M | 2.08 M | 2.18 M | - | 1.58 M | 1.29 M | 1.63 M | - | 891 K | 669 K | 528 K | - | 300 K | 1.88 M | 230 K | - | 200 K | 199 K | 205 K | - | 219 K | 1.46 M | 196 K | - | 117 K | 113 K | 133 K | - | - | - | - | - | - | - | - | - | - | - | - | - | 182 K | 220 K | - |
General and Administrative Expenses |
2.18 M | 2.13 M | 2.19 M | 1.31 M | - | 1.51 M | 2.65 M | 272 K | - | 1.26 M | 2.04 M | 2.33 M | - | 2.32 M | 2.44 M | 2.69 M | - | 2.42 M | 2.05 M | 2.12 M | - | 1.46 M | 1.25 M | 1.6 M | - | 891 K | 669 K | 528 K | - | 300 K | 1.88 M | 230 K | - | 200 K | 199 K | 205 K | - | 219 K | 1.46 M | 196 K | - | 117 K | 113 K | 133 K | - | 108 K | 174 K | 112 K | - | 124 K | 152 K | 197 K | - | 162 K | 168 K | 127 K | - | 182 K | 220 K | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company INVO Bioscience (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.